COST-EFFECTIVENESS OF SAXAGLIPTIN (ONGLYZA®) IN TYPE 2 DIABETES IN SOUTH AFRICA

被引：0
|
作者：
Juarez-Garcia, A. [1 ]
Casalvolone, D. [2 ]
Qatami, L. [3 ]
Bergenheim, K. [4 ]
Donato, B. M. K. [5 ]
机构：
[1] Bristol Myers Squibb Co, Mexico City, DF, Mexico
[2] Bristol Myers Squibb Co, Bedforview, South Africa
[3] Bristol Myers Squibb Co, Dubai, U Arab Emirates
[4] AstraZeneca, Molndal, Sweden
[5] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.974
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A180 / A180
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden
    Granstrom, Ola
    Bergenheim, Klas
    McEwan, Phil
    Sennfalt, Karin
    Henriksson, Martin
    PRIMARY CARE DIABETES, 2012, 6 (02) : 127 - 136
  • [2] Saxagliptin (Onglyza) for Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2009, 51 (1324): : 85 - 86
  • [3] Saxagliptin (Onglyza) for Type 2 Diabetes Mellitus
    Whalen, Karen
    St Onge, Erin
    AMERICAN FAMILY PHYSICIAN, 2010, 81 (12) : 1483 - 1484
  • [4] US Cost-Effectiveness of Saxagliptin in Type 2 Diabetes Mellitus
    Bergenheim, Klas
    Williams, Setareh A.
    Bergeson, Joette Gdovin
    Stern, Lee
    Sriprasert, Michelle
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2012, 4 (01) : 20 - 28
  • [5] Cost-Effectiveness of Saxagliptin in Type 2 Diabetes in the United States
    Bergenheim, Klas
    Williams, Setareh A.
    Bergeson, Joette G.
    Stern, Lee
    Sriprasert, Michelle
    DIABETES, 2011, 60 : A629 - A630
  • [6] COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN RUSSIA
    Arinina, E. E.
    Rashyd, M.
    VALUE IN HEALTH, 2012, 15 (04) : A172 - A172
  • [7] COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN SPAIN
    Ramirez de Arellano, A.
    Brosa, M.
    Franch, J.
    Mauricio, D.
    Alvarez, C.
    Sanchez-Zamorano, M.
    De Rivas, B.
    VALUE IN HEALTH, 2010, 13 (07) : A292 - A292
  • [8] Onglyza® (Saxagliptin) Receives Marketing Authorization in Europe for the Treatment of Type 2 Diabetes
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2010, 12 (01): : 88 - 88
  • [9] Saxagliptin (ONGLYZA™), receives positive opinion in Europe for the treatment of type 2 diabetes
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2009, 11 (09): : 912 - 912
  • [10] COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS ACARBOSE AS SECOND-LINE THERAPY IN TYPE 2 DIABETES IN CHINA
    Gu, S.
    Shao, H.
    Zeng, Y.
    Shi, L.
    Dong, H.
    VALUE IN HEALTH, 2016, 19 (07) : A898 - A898
12345